NCCN Guidelines for Patients® | Diffuse Large B-cell Lymphoma

25 NCCN Guidelines for Patients ® : Diffuse Large B-cell Lymphoma, 2017 In Part 3, the main treatment types for DLBCL are briefly described. Knowing what a treatment is will help you understand your treatment options listed in Part 4. There is more than one treatment for DLBCL. Not every person will receive every treatment described in this chapter. Immunotherapy The immune system is your body’s natural defense against disease. Immunotherapy increases the activity of this system. As a result, it improves your body’s ability to find and destroy cancer cells. Immunotherapy is a common treatment for DLBCL. Immunotherapy for DLBCL uses rituximab. It is an anti-CD20 monoclonal antibody. This human- made antibody attaches to CD20 on the surface of lymphoma cells. See Figure 8 . It works by marking the cells for destruction. It may directly kill cells, too. Rituximab is sold as Rituxan ® . It is a liquid that will be slowly injected into your vein (infusion). It often takes a few hours to receive the full dose. How often rituximab is received differs among people. Ask your doctor for more information. Rituximab is also sold as Rituxan Hycela ™ . This medicine is injected under the skin for treatment of certain lymphomas. Injections may be received after the first dose of rituximab by infusion. Also, injections may be an option as long as rituximab isn’t being used with ibritumomab tiuxetan. Injections last between 5 and 7 minutes. Figure 8 Anti-CD20 monoclonal antibody Anti-CD20 monoclonal antibodies attach to lymphoma cells to mark them for destruction by your immune system. Derivative work of Rituximab Binding to CD20 on a B Cell Surface by NIAID available at commons. Rituxima_Binding_to_CD20_on_a_B_Cell_Surface_(6830897205).jpg under a Creative Commons Attribution 2.0 Generic license 3 Overview of cancer treatments Immunotherapy